Sharma, M. R., Johnson, M. L., Puzanov, I., Sznol, M., Mckean, M., Gainor, J. F., Spira, A., Henick, B., Tolcher, A. W., Chen, C. T., El-Khoueiry, A., Broderick, J., Peng, L., Che, J., Cao, L., Wilson, D., Lathers, D., Horak, C., Feltquate, D., & Luke, J. J. (2024). 758 GLIMMER-01: phase 1/2 trial of a first-in-class bi-sialidase (E-602) in combination with cemiplimab in patients with PD-(L)1-resistant solid tumors. Regular and Young Investigator Award Abstracts, A862–A862. https://doi.org/10.1136/jitc-2024-sitc2024.0758

Li, F., Yang, Z., Savage, T. M., Vincent, R. L., de los Santos-Alexis, K., Ahn, A., Rouanne, M., Mariuzza, D. L., Danino, T., & Arpaia, N. (2024). Programmable bacteria synergize with PD-1 blockade to overcome cancer cell–intrinsic immune resistance mechanisms. Science Immunology, 9(100). https://doi.org/10.1126/sciimmunol.adn9879

Redenti, A., Im, J., Redenti, B., Li, F., Rouanne, M., Sheng, Z., Sun, W., Gurbatri, C. R., Huang, S., Komaranchath, M., Jang, Y., Hahn, J., Ballister, E. R., Vincent, R. L., Vardoshivilli, A., Danino, T., & Arpaia, N. (2024). Probiotic neoantigen delivery vectors for precision cancer immunotherapy. Nature, 635(8038), 453–461. https://doi.org/10.1038/s41586-024-08033-4

Liguori, F., Pellicciotta, N., Milanetti, E., Xi Windemuth, S., Ruocco, G., Di Leonardo, R., & Danino, T. (2024). Dynamic Gene Expression Mitigates Mutational Escape in Lysis-Driven Bacteria Cancer Therapy. BioDesign Research, 6. https://doi.org/10.34133/bdr.0049

Lee, I. Y., Hanft, S., Schulder, M., Judy, K. D., Wong, E. T., Elder, J. B., Evans, L. T., Zuccarello, M., Wu, J., Aulakh, S., Agarwal, V., Ramakrishna, R., Gill, B. J., Quiñones-Hinojosa, A., Brennan, C., Zacharia, B. E., Silva Correia, C. E., Diwanji, M., Pennock, G. K., … Boockvar, J. A. (2024). Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense Oligonucleotide in Newly Diagnosed Glioblastoma Patients. Future Oncology, 20(10), 579–591. https://doi.org/10.2217/fon-2023-0702

Gurbatri, C. R., Radford, G. A., Vrbanac, L., Im, J., Thomas, E. M., Coker, C., Taylor, S. R., Jang, Y., Sivan, A., Rhee, K., Saleh, A. A., Chien, T., Zandkarimi, F., Lia, I., Lannagan, T. R. M., Wang, T., Wright, J. A., Kobayashi, H., Ng, J. Q., … Danino, T. (2024). Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-44776-4

Okolo, O., Honzel, E., Britton, W. R., Yu, V. X., Flashner, S., Martin, C., Nakagawa, H., & Parikh, A. S. (2023). Experimental Modeling of Host–Bacterial Interactions in Head and Neck Squamous Cell Carcinoma. Cancers, 15(24), 5810. https://doi.org/10.3390/cancers15245810

O’Cearbhaill, R. E., Moore, K. N., Yeku, O., Liu, J. F., Bouberhan, S., Hamilton, E. P., Hou, J. Y., Van Nieuwenhuysen, E., Papadimitriou, K., Yoo, S.-Y., Govindraj, S., Brouwer-Visser, J., Peterman, M., Schmidt, T., Barnes, B., Madia, P., Zhu, M., Uldrick, T. S., Miller, E. A., & O’Malley, D. (2023). 754P Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study. Annals of Oncology, 34, S516–S517. https://doi.org/10.1016/j.annonc.2023.09.1933

Kokossis, D., Wei, H.-J., Gallitto, M., Yoh, N., McQuillan, N., Tazhibi, M., Berg, X., Zhang, X., Szalontay, L., Gartrell, R. D., Pavisic, J., Zhang, Z., Molotkov, A., Mintz, A., Konofagou, E. E., & Wu, C.-C. (2023). SURG-06. ENHANCED DELIVERY OF ANTI-PD1 FOR TREATMENT OF DIFFUSE MIDLINE GLIOMA USING FOCUSED ULTRASOUND-MEDIATED BLOOD-BRAIN BARRIER OPENING. Neuro-Oncology, 25(Supplement_1), i73–i73. https://doi.org/10.1093/neuonc/noad073.282

Wang, Y.-C., Kelso, A. A., Karamafrooz, A., Chen, Y.-H., Chen, W.-K., Cheng, C.-T., Qi, Y., Gu, L., Malkas, L., Taglialatela, A., Kung, H.-J., Moldovan, G.-L., Ciccia, A., Stark, J. M., & Ann, D. K. (2023). Arginine shortage induces replication stress and confers genotoxic resistance by inhibiting histone H4 translation and promoting PCNA ubiquitination. Cell Reports, 42(4), 112296. https://doi.org/10.1016/j.celrep.2023.112296

Savage, T. M., Vincent, R. L., Rae, S. S., Huang, L. H., Ahn, A., Pu, K., Li, F., de los Santos-Alexis, K., Coker, C., Danino, T., & Arpaia, N. (2023). Chemokines expressed by engineered bacteria recruit and orchestrate antitumor immunity. Science Advances, 9(10). https://doi.org/10.1126/sciadv.adc9436

Fine, R. L., Mao, Y., Garcia-Carracedo, D., Su, G. H., Qiu, W., Hochfeld, U., Nichols, G., Li, Y.-L., Dinnen, R. D., Raffo, A., & Brandt-Rauf, P. W. (2023). Gene Therapy with p14/tBID Induces Selective and Synergistic Apoptosis in Mutant Ras and Mutant p53 Cancer Cells In Vitro and In Vivo. Biomedicines, 11(2), 258. https://doi.org/10.3390/biomedicines11020258

Hsu, D. J., Gao, J., Yamaguchi, N., Pinzaru, A., Wu, Q., Mandayam, N., Liberti, M., Heissel, S., Alwaseem, H., Tavazoie, S., & Tavazoie, S. F. (2023). Arginine limitation drives a directed codon-dependent DNA sequence evolution response in colorectal cancer cells. Science Advances, 9(1). https://doi.org/10.1126/sciadv.ade9120

Deb, D., Wu, Y., Coker, C., Harimoto, T., Huang, R., & Danino, T. (2022). Design of combination therapy for engineered bacterial therapeutics in non-small cell lung cancer. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-26105-1

Wen, P. Y., Reardon, D. A., Forst, D., Lee, E., Daoud, T., Berthoud, T., Soare, C., Diaz-Mitoma, F., Anderson, D. E., Lassman, A., & Iwamoto, F. (2022). CTIM-14. COMPREHENSIVE BIOMARKER ANALYSIS OF RESPONDERS AND NON-RESPONDERS IN A PHASE IIA TRIAL OF A CMV VACCINE IMMUNOTHERAPEUTIC CANDIDATE (VBI-1901). Neuro-Oncology, 24(Supplement_7), vii62–vii62. https://doi.org/10.1093/neuonc/noac209.246

Sharma, M., Lathers, D., Johnson, M., Luke, J., Puzanov, I., Curti, B., Chen, C., El-Khoueiry, A., Henick, B., Callahan, M., Sznol, M., Patel, S., Wilson, D., Ricker, M., Cao, L., Jayaraman, P., Che, J., Peng, L., Feltquate, D., … Tolcher, A. (2022). 772 A phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01). Regular and Young Investigator Award Abstracts, A803–A803. https://doi.org/10.1136/jitc-2022-sitc2022.0772

Park, K. W., Yang, H., Lee, M. G., Ock, S. A., Wi, H., Lee, P., Hwang, I.-S., Yoo, J. G., Park, C.-K., & Lee, B. R. (2022). Establishment of intestinal organoids from small intestine of growing cattle (12 months old). Journal of Animal Science and Technology, 64(6), 1105–1116. https://doi.org/10.5187/jast.2022.e70

Iwamoto, F., Tanguturi, S., Desai, A., Nayak, L., Uhlmann, E., Wang, T., Lustig, R., Hertan, L., Bagley, S., Hayden, J., Laforest-Roys, C., Muzikansky, A., McCluskey, C., Chukwueke, U., McFaline-Figueroa, J. R., Lee, E., Wen, P. Y., & Reardon, D. (2022). CTIM-18. PHASE 2 STUDY OF PD-1 BLOCKADE WITH PEMBROLIZUMAB PLUS RE-IRRADIATION FOR RECURRENT GLIOBLASTOMA (RGBM) (NCT03661723). Neuro-Oncology, 24(Supplement_7), vii63–vii64. https://doi.org/10.1093/neuonc/noac209.250

Pan, P., Haggiagi, A., & Iwamoto, F. (2022). BIOM-12. PROLONGED RESPONSE TO THIRD-LINE TREATMENT WITH COMBINATION CCNU/TMZ IN AN MGMT METHYLATED IDH-WILDTYPE GLIOBLASTOMA. Neuro-Oncology, 24(Supplement_7), vii6–vii6. https://doi.org/10.1093/neuonc/noac209.022

Liau, L. M., Ashkan, K., Brem, S., Campian, J., Trusheim, J., Iwamoto, F., Tran, D., Anstass, G., Cobbs, C., Heth, J., Salacz, M., D’Andre, S., Aiken, R., Moshel, Y., Nam, J., Pillainayagam, C., Wagner, S., Walter, K., Chaudary, R., … Bosch, M. (2022). CTIM-27. AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELL VACCINATION IMPROVES SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: SURVIVAL RESULTS FROM A PHASE 3 TRIAL. Neuro-Oncology, 24(Supplement_7), vii66–vii66. https://doi.org/10.1093/neuonc/noac209.259

He, D., Feng, H., Sundberg, B., Yang, J., Powers, J., Christian, A. H., Wilkinson, J. E., Monnin, C., Avizonis, D., Thomas, C. J., Friedman, R. A., Kluger, M. D., Hollingsworth, M. A., Grandgenett, P. M., Klute, K. A., Toste, F. D., Chang, C. J., & Chio, I. I. C. (2022). Methionine oxidation activates pyruvate kinase M2 to promote pancreatic cancer metastasis. Molecular Cell, 82(16), 3045-3060.e11. https://doi.org/10.1016/j.molcel.2022.06.005

Arrillaga-Romany, I., Kurz, S., Tarapore, R., Lu, G., Sumrall, A., Butowski, N., Harrison, R., DeGroot, J., Chi, A., Shonka, N., Umemura, Y., Odia, Y., Mehta, M., Nghiemphu, P., Cloughesy, T., Taylor, L., Graber, J., Kilburn, L., Dixit, K., … Wen, P. (2022). SYST-14 CLINICAL EFFICACY OF ONC201 IN RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA (DMG) PATIENTS. Neuro-Oncology Advances, 4(Supplement_1), i24–i24. https://doi.org/10.1093/noajnl/vdac078.093

Harimoto, T., Hahn, J., Chen, Y.-Y., Im, J., Zhang, J., Hou, N., Li, F., Coker, C., Gray, K., Harr, N., Chowdhury, S., Pu, K., Nimura, C., Arpaia, N., Leong, K. W., & Danino, T. (2022). A programmable encapsulation system improves delivery of therapeutic bacteria in mice. Nature Biotechnology, 40(8), 1259–1269. https://doi.org/10.1038/s41587-022-01244-y

Yu, X., Gao, S., Wu, D., Li, Z., Mi, Y., Yang, T., Sun, F., Wang, L., Liu, R., He, S., Ge, Q., Lv, Y., Xu, A. (Yuanguang), & Zeng, H. (2022). Bone Tumor Suppression in Rabbits by Hyperthermia below the Clinical Safety Limit Using Aligned Magnetic Bone Cement (Small 3/2022). Small, 18(3). Portico. https://doi.org/10.1002/smll.202270012